Monoclonal antibodies clear amyloid plaques but only modestly preserve cognition for patients with early Alzheimer disease, MCI.

Statistical analysis on ADAS-cog was performed using all available on-treatment data. Beginning with Month 3, there were 127 subjects in the placebo group and 126 subjects in the 5 mg/day dose group ...

Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD Improvement in cognition measured by ADAS-Cog 11 at three months is ...

BioVie is set to report topline data from its Phase 3 trial in Alzheimer's disease, with a high likelihood of reaching statistical significance. Blinded data from the trial showed a reduction in ...

Sept. 2 -- TUESDAY, Sept. 2 (HealthDay News) -- Exercise may help treat memory problems in adults, according to new research from Australia. The study, focused on 138 people age 50 and older at ...

Clinical trials in Alzheimer disease (AD) generally allow participants to continue receiving concomitant medications, including cholinesterase inhibitors (ChEIs) and memantine, if the dose is stable.

Aerobic-resistance exercises and computerized cognitive training improved brain power in older adults with mild cognitive impairments. But add vitamin D into the mix — thought to be linked with better ...